Pembrolizumab monotherapy and combination therapy fails to meet primary endpoint in study for advanced metastatic urothelial cancer

In the KEYNOTE-361 study, there was no improvement in overall, or progression free survival for pembrolizumab in combination with chemotherapy, vs chemotherapy alone. The monotherapy arm was not formally tested as the combination arm did not achieve superiority.


Biospace Inc.